Oura Health disclosed in May 2026 that it has filed confidential paperwork for an initial public offering, aiming to list later this year. The company was valued at $11 billion in October 2025 after closing a $900 million Series E round led by Fidelity Management. The U.S. Department of Defense is a customer, and academic medical centers use the rings in research studies.
Cyborg Score Rationale
Oura demonstrates exceptional growth momentum with revenue doubling to ~$1B in 2025 and clear path to $1.5B+ in 2026. The company has secured elite funding ($11B valuation, Series E from Fidelity), strong institutional adoption (DoD, academic centers), and is positioned for IPO. Primary risk: intensifying competition from well-capitalized rivals.
Top Insights
Acquired Galen AI in April 2026, signaling AI-driven health analytics expansion
Facing intensifying competition from cheaper rivals including RingConn at $279 and India's Ultrahuman, though maintaining market leadership
Membership base approaching 5 million users with strong retention, underpinning recurring revenue model
Sold 5.5 million rings to date as of September 2025, up from 2.5 million in June 2024, demonstrating accelerating hardware adoption
Named Competitors
Apple Watch — Leading smartwatch with health tracking capabilities
Garmin — Premium fitness and health wearables
RingConn — Budget-friendly smart ring alternative
Ultrahuman — Affordable health tracking ring from India
Zepp Health — Amazfit and wearable health ecosystem
Recent Developments
(May 2026) Filed confidentially with SEC for initial public offering
(April 2026) Acquired Galen AI
(October 2025) Closed $900 million Series E round at $11 billion valuation
(2025) Revenue roughly doubled to about $1 billion
Open the full interactive Oura Health Oy report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.